Vinblastine and prednisolone as adjunctive therapy for canine cutaneous mast cell tumors.
Twenty-seven dogs with inadequately excised, cutaneous mast cell tumors (MCT; 20 residual microscopic disease, seven marginal excision) were treated with a vinblastine and prednisolone chemotherapeutic protocol. Twenty dogs were available for follow-up examination after 12 months. One dog suffered local recurrence of the tumor, four dogs developed new cutaneous tumors, and one dog had both events. Fourteen dogs were free of MCT. There was no confirmed tumor-related mortality. Although toxicity from the chemotherapy was generally mild, one dog died of sepsis during treatment.
Davies
David R
DR
Division of Veterinary and Biomedical Sciences, Murdoch University, Murdoch, Western Australia, Australia.
Wyatt
Kenneth M
KM
Jardine
John E
JE
Robertson
Ian D
ID
Irwin
Peter J
PJ
D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant / Q000379:methods / Q000662:veterinary; D004283:Dog Diseases / Q000188:drug therapy* / Q000473:pathology; D004285:Dogs; D005260:Female; D008297:Male; D034801:Mastocytoma / Q000188:drug therapy / Q000473:pathology / Q000662:veterinary*; D009367:Neoplasm Staging / Q000662:veterinary; D011239:Prednisolone / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000662:veterinary*; D016896:Treatment Outcome; D014747:Vinblastine / Q000627:therapeutic use*
D018931:Antineoplastic Agents, Hormonal; D000972:Antineoplastic Agents, Phytogenic; D014747:Vinblastine; D011239:Prednisolone